- Screening
- Baseline
- In the process of the treatment
- At the end of the treatment
- Follow-up 1
- Follow-up 2
- Follow-up 3
- Management system of participants
- Speciman management system
- Data management system
- ADR/ADE management system
- Madicine management system
- Instruments management system
- SOPs
- Research team
- Design, Methods
- Management of the progress
- General information
- Physical examination
- Blood Routine Tests
- Urine and Stool Routine Tests
- Blood Electrolytes Tests
- Coagulation Function Tests
- Serum Liver Function Tests
- HBV Markers Test
- Renel Function Test
- Heat Function Examination
- Blood Cell Morphology
- Image Examinations
- Nervous System Examination
- Lung Function Examination
- Blood Gas Analysis
- Physical Ability Examination
- Health Relative Quality of Life
Weight (week 2) | 69.0 |
BMI (week 2) | 25.0 |
Weight (week 2) | 69.8 |
Height (start) | 167 |
diastolic pressure (start) | 81 |
systolic pressure (start) | 131 |
BMI (start) | 25.0 |
Weight (start) | 69.8 |
BMI (week 4) | 24.7 |
IFABP (start) | 1.2 |
TNF-a (start) | 0.9 |
IL-6 (start) | 0.8 |
HbA1C (start) | 7.5 |
GLU-2hr (start) | 154 |
GLU-AC (start) | 141 |
TG (start) | 122 |
- Management for Progress
- Physical examination
- Blood Routine Tests
- Urine and Stool Routine Tests
- Serum Electrolytes Tests
- Liver Function Tests
- HBV Markers Test
- Renel Function Test
- Heat Function Examination
- Image Examinations
- Blood Cell Morphology
- Nervous System Examination
- Lung Function Examination
- Blood Gas Analysis
- Physical Sbility Examination
- Health Relative Quality of Life
diastolic pressure (week 6) | 76.0 |
systolic pressure (week 6) | 123.0 |
BMI (week 6) | 25.1 |
Weight (week 6) | 70.1 |
IFABP (end) | 1.3 |
TNF-a (end) | 1.0 |
IL-6 (end) | 1.2 |
HbA1C (end) | 6.4 |
GLU-2hr (end) |
|
GLU-AC (end) | 117.0 |
TG (end) | 46.0 |